We are live on ! Find out more
ATRS

Antares Pharma, Inc.
ATRS

Delisted

ATRS was delisted on the 23rd of May, 2022.

Back to rankings

82 hedge funds and large institutions have $76.8M invested in Antares Pharma, Inc. in 2014 Q3 according to their latest regulatory filings, with 11 funds opening new positions, 24 increasing their positions, 30 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

4% less funds holding

Funds holding: 85 → 82 (-3)

20% less repeat investments, than reductions

Existing positions increased: 24 | Existing positions reduced: 30

21% less first-time investments, than exits

New positions opened: 11 | Existing positions closed: 14

38% less capital invested

Capital invested by funds: $123M → $76.8M (-$46.1M)

96% less call options, than puts

Call options by funds: $14K | Put options by funds: $354K

Holders
82
Holders Change
-3
Holders Change %
-3.53%
% of All Funds
2.37%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
11
Increased
24
Reduced
30
Closed
14
Calls
$14K
Puts
$354K
Net Calls
-$340K
Net Calls Change
+$117K

Top Buyers

Rank Fund Capital Flow
1
GTC
Ghost Tree Capital
New York
+$2.4M
2
BC
Broadfin Capital
New York
+$1.42M
3
Renaissance Technologies
Renaissance Technologies
New York
+$318K
4
Citadel Advisors
Citadel Advisors
Florida
+$289K
5
TC
TFS Capital
Pennsylvania
+$258K

Top Sellers

Rank Fund Capital Flow
1
DM
Deerfield Management
New York
-$3.88M
2
ACM
Ashford Capital Management
Delaware
-$2.91M
3
UBS AM
UBS AM
Illinois
-$2.1M
4
Millennium Management
Millennium Management
New York
-$1.37M
5
Allianz Asset Management
Allianz Asset Management
Germany
-$1.07M

ATRS Hedge Fund Activity: Q3 2014 in Review

82 of the 3,455 institutional investors tracked by Wall St. Rank reported a position in Antares Pharma, Inc. (ATRS) for Q3 2014, worth a combined $76.8M — down 38% from $123M a quarter earlier.

Sellers outnumbered buyers: 14 funds closed out of ATRS and 11 opened new positions — a net loss of 3 holders — while 30 trimmed existing stakes and 24 added.

The largest buyer was Ghost Tree Capital, opening a new position worth an estimated $2.4M. The largest seller was Deerfield Management, cutting an estimated $3.88M.

  • 82 institutional investors held Antares Pharma, Inc. (ATRS) as of Q3 2014, down from 85 in Q2 2014.
  • Funds reported $76.8M of Antares Pharma, Inc. stock for Q3 2014, down 38% quarter-over-quarter.
  • 11 funds opened new Antares Pharma, Inc. positions in Q3 2014 and 14 closed out, a net change of -3 holders.
  • The largest Antares Pharma, Inc. buyer in Q3 2014 was Ghost Tree Capital, an estimated $2.4M added.
  • The largest Antares Pharma, Inc. seller in Q3 2014 was Deerfield Management, an estimated $3.88M sold.

Based on aggregated 13F filings for Q3 2014.